Trial Profile
A Double-blind, Placebo-controlled, Randomized, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Bms-512148 in Diabetic Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 06 Jan 2011 Actual end date (Aug 2005) added as reported by ClinicalTrials.gov.
- 13 Sep 2008 New trial record.